ARID1A and ovarian clear cell cancer: Thus, GSK126exhibits potential as a molecular targeted drug that inhibits the proliferation of ARID1A-mutated ovarian clear cell carcinoma cells by targeting and inhibiting EZH2. The clinical application of drugs that target and inhibit EZH2 require further examination of the status of ARID1A mutations in OCCC.